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Abstract
Emergence of clones carrying point mutations in the BCR-ABL1 kinase domain 
(KD) is a common mechanism of resistance to tyrosine kinase inhibitor (TKI)-based 
therapies in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia 
(ALL). Sanger sequencing (SS) is the most frequently used method for diagnostic 
BCR-ABL1 KD mutation screening, but it has some limitations—it is poorly sensi-
tive and cannot robustly identify compound mutations. Next-generation sequencing 
(NGS) may overcome these problems. NSG is increasingly available and has the 
potential to become the method of choice for diagnostic BCR-ABL1 KD mutation 
screening. A group discussion within an ad hoc constituted Panel of Experts has pro-
duced a series of consensus-based statements on the potential value of NGS testing 
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1 |  INTRODUCTION
The introduction of tyrosine kinase inhibitors (TKIs) for the 
treatment of adult Philadelphia-positive (Ph+) acute lymphoblas-
tic leukemia (ALL) has dramatically increased complete hema-
tological response (CHR) rates from 60%-70% to 95%-100% and 
extended 5-year overall survival (OS) from 20% up to 50%.1,2 
A number of studies have tested the combination of TKIs with 
more or less intensive chemotherapy regimens and schedules and 
even the use of chemotherapy-free approaches, first in elderly and 
unfit patients and more recently in unselected adult patients.3-5 
In all studies, when relapses occurred, point mutations in the 
BCR-ABL1 kinase domain (KD) were detected in 50%-80% of 
patients.5 These mutations displayed high IC50 values in bio-
chemical and cellular assays6-8 implying that they have a direct 
causal role in TKI resistance.9-13 The most frequent imatinib-re-
sistant mutation in Ph+ ALL patients is the T315I,14,15 against 
whom second-generation TKIs (2GTKIs), but not ponatinib or 
monoclonal antibodies, are ineffective.16-19 Patients positive for 
mutations exhibit a particularly high degree of genetic instability, 
which may foster the acquisition of additional mutations in the 
same (“compound” mutations) or in different (“polyclonal” mu-
tations) Ph+ subpopulations, generating complex mutation land-
scapes.20,21 Compound mutations are particularly challenging to 
address, since IC50 data suggest that they are highly resistant to 
imatinib and all second-generation TKIs.22
There is increasing evidence that a rational use of mini-
mal residual disease (MRD) monitoring and BCR-ABL1 KD 
mutation screening may play an important role in treatment 
optimization.23,24 However, in contrast to chronic myeloid 
leukemia (CML), recommendations on when and how to 
perform BCR-ABL1 KD mutation screening in Ph+ ALL 
have never been produced. Mutation testing is commonly 
performed by bidirectional Sanger sequencing (SS) of the 
entire BCR-ABL1 KD amplified by polymerase chain reac-
tion.25 However, SS fails to reveal the presence of mutations 
when they are present in less than 10%-20% of BCR-ABL1 
transcripts.25 Thus, a number of alternative methodologies, 
including next-generation sequencing (NGS), have been 
proposed to facilitate earlier detection of mutant, potentially 
resistant BCR-ABL1-positive cells.26-34 Routine NGS test-
ing is being implemented in a greater and greater number 
of diagnostic laboratories. It is well documented that NGS 
is markedly superior to SS in terms of sensitivity, and can 
additionally allow straightforward identification of the most 
frequent compound mutations.26-34 However, very few data 
are available on the clinical impact of BCR-ABL1 KD muta-
tion testing by NGS in patients with Ph+ ALL, and this does 
not allow the formulation of evidence-based recommenda-
tions. The aim of this project was thus to generate consen-
sus-based indications for the possible clinical use of NGS in 
Ph+ ALL.
2 |  METHODS
A Panel of Experts was appointed on the basis of their nation-
ally and internationally recognized expertise in the treatment 
and molecular monitoring of ALL. An initial meeting was 
held in June 2018, during which the outline of the project was 
defined and the topics of the expert discussion were decided. 
A series of key questions were identified and addressed 
through questionnaires. Each panelist drafted statements 
related to one or a few questions, while the remaining pan-
elists scored their agreement with those statements or pro-
vided suggestions for modifications. Subsequently, the Panel 
convened for a consensus conference in Milan in November 
2018, where final proposals were defined using the nominal 
group technique.35 Briefly, Panel members were first asked 
to comment in a round-robin fashion on their disagreements 
on each issue, and then to vote for a final statement.
3 |  RESULTS
3.1 | NGS testing before and during 
frontline treatment
When using highly sensitive methods of detection, BCR-
ABL1 KD mutations have been identified in de novo Ph+ 
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before and during first-line TKI-based treatment, in relapsed/refractory cases, before 
and after allo-stem cell transplantation, and on how NGS results may impact on thera-
peutic decisions. A set of minimal technical and methodological requirements for 
the analysis and the reporting of results has also been defined. The proposals herein 
reported may be used to guide the practical use of NGS for BCR-ABL1 KD mutation 
testing in Ph+ ALL.
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ALL.10,12,13,29,36-39 Some patients, in particular, may already 
be harboring the pan-resistant T315I mutation at the time of 
diagnosis.12,36,39
Using denaturing high-performance liquid chromatog-
raphy (D-HPLC), Pfeifer et al12 documented the detec-
tion of a KD mutation in 41% of Ph+ ALL patients prior 
to induction therapy. The frequency of the mutant allele 
was always low, ranging from 0.1% to 2% (median, 0.5%). 
Patients were enrolled in a prospective, randomized clini-
cal trial of the German Multicenter Study Group for Adult 
ALL, exploring frontline imatinib-based therapy in elderly 
patients, and were randomly assigned to receive a 4-week 
induction with either imatinib or chemotherapy followed 
by extended therapy with imatinib plus chemotherapy. 
Pretherapy mutations were not associated with a poorer he-
matologic or molecular remission rate or shorter remission 
duration. Despite the high complete response rate, how-
ever, all but two patients who were initially found to have a 
KD mutation, and did not die in complete response, subse-
quently relapsed. At relapse, the dominant clone showed an 
identical mutation in 90% of cases, suggesting selection of 
the pre-therapy mutation. Only one patient relapsed with a 
different mutation.
Rousselot et al37 retrospectively performed allele-specific 
oligonucleotide polymerase chain reaction (ASO-PCR) on 
baseline samples available from 43 cases enrolled in a clini-
cal trial of low-intensity chemotherapy plus dasatinib in Ph+ 
ALL patients older than 55 years. The analysis showed that in 
10/43 samples a T315I mutation was already present at very 
low levels at diagnosis. Eight of these 10 patients relapsed, 
all with the T315I mutation; of the 2 who did not relapse, one 
patient was transplanted and was still in complete response 
54 months after allogeneic hematopoietic stem cell transplant 
(allo-SCT) and the other died in CHR at 9.6  months from 
lung adenocarcinoma. Additional anecdotal cases in which 
the mutation detected at the time of relapse could be traced 
back to the pretherapy or diagnosis sample can be found in 
the literature.10,13,29,39
Real-time PCR-based assessment of residual BCR-ABL1 
transcript levels in Ph+ ALL patients is universally accepted 
as a strong prognostic factor and is performed at regular inter-
vals during treatment.40 Persistence of MRD positivity and/
or MRD increase may predict the emergence of TKI-resistant 
BCR-ABL1 KD mutations.29 NGS-based monitoring of the 
dynamics of emerging BCR-ABL1 mutations in parallel to 
MRD assessment may thus provide meaningful information 
on the subclonal sensitivity of Ph+ leukemic cells to the cur-
rent therapy. As a matter of fact, a strikingly rapid expansion 
of the mutated clones as early as after 4 weeks since TKI ini-
tiation was observed,29,36 suggesting that, at least in a propor-
tion of patients, the mechanism of therapy resistance may be 
due to the selection of preexisting mutated clones rather than 
or in addition to the induction of new mutations. Thus, only 
serial and frequent monitoring can intercept the very initial 
phases of clonal selection.
3.1.1 | Consensus statements
BCR-ABL1 KD mutation testing by NGS is indicated in pa-
tients with Ph+ ALL before frontline treatment. The Panel 
argued that the detection of BCR-ABL1 KD mutations that 
might lead to the emergence of TKI-resistant clones could 
allow the identification of patients at a higher risk of MRD 
persistence and early relapse, and help in planning an indi-
vidualized molecular and mutation monitoring.
In patients with pretherapy low-level mutations known 
to confer resistance to one or more TKIs, monthly retesting 
should be performed to monitor mutation kinetics, until re-
sidual BCR-ABL1 transcript levels decrease below 0.1%, or 
until the increase in mutation and BCR-ABL1 transcript lev-
els leads to therapeutic intervention.
3.2 | NGS testing in refractory and 
relapsing patients
Relapses after therapy may be associated with the emergence 
or persistence of clones harboring mutations that confer re-
sistance to the TKI incorporated in the treatment regimen. 
Since for each TKI there is a well-defined spectrum of sen-
sitive and resistant mutations, an accurate assessment of 
BCR-ABL1 KD mutation status is important for treatment 
decision-making.
Using NGS, Soverini et al28 analyzed longitudinally 106 
samples from 33 patients with CML or Ph+ ALL who had 
received multiple lines of TKI treatment and who had expe-
rienced sequential relapses accompanied by the emergence 
of one or more mutations. They found that SS had misclas-
sified or underestimated the BCR-ABL1 KD mutational sta-
tus in 55% of samples. Indeed, low-level mutations were 
detected not only in SS-negative patients, but also in addi-
tion to the dominant clone(s) detected by SS. Compound 
mutations were frequent in advanced phase CML and in 
Ph+ ALL, and could easily be recognized by NGS in the 
majority of cases. In another study,29 Soverini et al ana-
lyzed by NGS 106 samples from 34 patients with Ph+ ALL 
who relapsed after first (n = 10 pts) or second/subsequent 
line (n = 24) of TKI treatment in an attempt to “backtrack” 
mutation emergence. NGS detected resistance-driver muta-
tions earlier than SS in 41% of patients. All samples posi-
tive for low-level mutations had persistently high or rising 
levels of MRD. NGS of the BCR-ABL1 KD proved capable 
of anticipating an impending recurrence with a median of 
5 weeks (range, 4-14 weeks) compared to the classical SS-
based analysis.
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3.2.1 | Consensus statements
BCR-ABL1 KD mutation testing by NGS is indicated in pa-
tients who do not reach a CHR after induction therapy.
BCR-ABL1 KD mutation testing by NGS is also indicated 
in patients who do not reach a complete molecular response 
after induction therapy. In the latter, however, the BCR-ABL1 
transcript level should be >0.1% to ensure the feasibility of 
NGS library preparation. Given the variability of the induc-
tion protocols, at least 4 weeks of induction therapy should be 
completed before NGS testing.
BCR-ABL1 KD mutation testing by NGS testing is indi-
cated in patients with a relapsing disease before receiving sal-
vage therapy. The Panel argued that the information provided 
by NGS testing in refractory and relapsing patients may allow 
the personalization of an optimal TKI treatment choice.
3.3 | NGS testing before and after allogeneic 
hematopoietic stem cell transplant
Allogeneic hematopoietic stem cell transplant (allo-SCT) 
is still considered the best option in attempting to pursue 
long-term disease control in Ph+ ALL.23 According to the 
European Group for Blood and Marrow Transplantation, pa-
tients with undetectable MRD after allo-SCT may be treated 
prophylactically or, alternatively, may be monitored and re-
ceive a TKI only if and when they convert to MRD-positivity, 
whereas patients with detectable MRD after allo-SCT should 
be started on TKI treatment as soon as possible.41
Several retrospective, comparative analyses have been 
performed with the aim of evaluating the impact of the use 
of TKIs after allo-SCT on outcome. The largest analysis, re-
stricted to patients treated with allo-SCT in first complete 
remission, showed that imatinib or dasatinib for primary 
prophylaxis against relapse resulted in an improvement of 
OS and leukemia-free survival along with a lower incidence 
of grade 2-4 acute graft versus host disease.42 Although the 
study had some important limitations associated with its ret-
rospective nature, the results provide a strong rationale for the 
use of TKIs as maintenance after allo-SCT for patients with 
Ph+ ALL in first remission.
Unfortunately, TKI resistance mechanisms in the trans-
plantation setting have not been extensively investigated; 
indeed, there are very few data about the mutational status 
of MRD-positive patients both before and after allo-SCT, as 
well as about the patterns of clonal evolution of preexisting 
mutations. Egan et al43 have shown that Ph+ leukemia pa-
tients harboring BCR-ABL1 KD mutations before allo-SCT 
predominantly relapse with the same mutation. Therefore, 
empiric selection of any one TKI in the posttransplant man-
agement will almost certainly result in predictable treatment 
failures in a subset of patients with preexisting mutations. In 
addition to considerations of cost and toxicity, the pretrans-
plant mutation status of patients with detectable residual dis-
ease should thus be considered when choosing the TKI for 
posttransplant prophylaxis.
3.3.1 | Consensus statements
The Panel agreed that knowledge of the BCR-ABL1 KD muta-
tion status prior to an allo-SCT could provide useful informa-
tion about the risk of recurrence of the disease after transplant 
and about the posttransplant TKI to be utilized. Thus, patients 
who did not have NGS testing done at the time of transplant 
decision should have it carried out prior to the transplant (if 
the BCR-ABL1 transcript level is greater than 0.1%).
After transplant, BCR-ABL1 KD mutation screening by 
NGS should be performed whenever a patient tests MRD 
positive, with BCR-ABL1 levels greater than 0.1%. If a low-
level mutation is detected, mutation kinetics should be moni-
tored at monthly intervals, and the TKI to which the mutation 
is known to confer resistance should be avoided.
3.4 | Impact of NGS 
on therapeutic decisions
In Ph+ ALL patients who fail imatinib treatment, BCR-
ABL1 mutation profiling may be useful before changing 
therapy since the detection of specific mutations may in-
fluence the choice of the second-generation TKI.23,24 This 
is particularly relevant now that the approval of ponatinib 
offers significant chances to rescue patients with the T315I 
or with multiple mutations predicted to result in insensi-
tivity to both dasatinib and nilotinib.44 Detailed lists of 
imatinib-, dasatinib-, nilotinib-, and bosutinib-resistant 
mutations are available to support clinicians in this deci-
sion-making.5 However, even though scientifically sound, 
the hypothesis that mutation-guided TKI selection would 
result in better outcomes than an empirically based TKI 
selection has not yet been tested and validated in prospec-
tive clinical trials.
The setting in which the greater sensitivity of NGS could 
be most useful is when a Ph+ ALL patient with a nonoptimal 
response to imatinib has to be shifted to second-line therapy, 
and in the transplant setting. Typically, patients candidate 
for the use of second-generation TKIs in the pretransplant 
or posttransplant setting are represented by those who have 
experienced resistance to pretransplant treatment with ima-
tinib. In fact, in the posttransplant setting, early prophylactic 
or MRD-triggered imatinib was not always effective in reduc-
ing the risk of clinical or molecular relapse.45 Nilotinib has 
been tested after SCT in a single prospective trial,46 whereas 
dasatinib only in small retrospective cohorts.47-50 The use 
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of third-generation TKIs, such as ponatinib, as maintenance 
after allo-SCT has not been reported so far. Thus, there are no 
accepted criteria for choosing an alternative TKI after ima-
tinib, and this decision should be based both on the safety 
profile and on the predictable efficacy.
3.4.1 | Consensus statements
In general, the interpretation of NGS testing results and the 
therapeutic decisions should involve both biologists/biotech-
nologists and physicians expert in Ph+ ALL monitoring and 
treatment, respectively.
Since there is no established evidence of a real clinical 
advantage of a personalized therapy tailored according to 
the detection of low-level mutations, at the present time, any 
therapeutic decision based on the results of NGS testing may 
only derive from inductive reasoning.
The majority of Panel members agreed that the NGS re-
sults obtained prior to front-line therapy should restrain from 
modifying the approved conventional treatment, but should 
rather trigger monthly evaluation of mutation kinetics (in the 
presence of quantifiable disease).
On the contrary, the identification of a low-level BCR-
ABL1 KD mutation by NGS in patients who are MRD-positive 
after TKI-based induction or consolidation should prompt to 
consider switching TKI when the mutation is known to be not 
sensitive to the TKI currently used by the patient. In this case, 
the detection of mutations by NGS should encourage an in-
dividualized therapy or a therapeutic switch that depends on 
the type and level of mutation(s) and on the toxicity profile 
of the various options.
The Panel claimed that BCR-ABL1 KD mutation testing 
by NGS has an important role in patients who are candidate 
for the posttransplant use of TKIs in order to reduce the risk 
of relapse. In the case of persistence or reappearance of MRD 
positivity after allo-SCT, the choice of an alternative TKI 
should be based on the results of NGS analysis.
3.5 | Strength of indications of NGS 
testing and logistic issues
The Panel addressed the matter of how mandatory the indica-
tions for the use of NGS testing for BCR-ABL1 KD mutation 
issued by this document should be for clinical centers that 
do not have access to the NGS technology. The Panel agreed 
that NGS testing should be encouraged, in the proper indica-
tions of use, in all the clinical centers caring for patients with 
Ph+ ALL. However, the Panel also acknowledged that there 
is currently no evidence demonstrating that the lack of NGS 
testing hampers the possibility to properly manage Ph+ ALL 
patients, thus failure to use NGS because of the lack of access 
to it, at present, should not be regarded as an inappropriate 
clinical management.
The Panel also advocated that NGS testing should be per-
formed in a restricted number of highly qualified laborato-
ries within regional or national networks, already engaged in 
MRD monitoring of Ph+ ALL patients. Important aims of 
these networks should be: centralization of the analysis in a 
few highly specialized laboratories; harmonization of tech-
niques among the network laboratories; central coordination 
for continuous technology development and also through 
worldwide collaborations with other reference laboratories; 
development of an inter-lab quality control system for sensi-
tivity, accuracy, and reproducibility of the results; organiza-
tion of periodical quality control rounds.
3.6 | Performance characteristics of NGS 
testing in Ph+ ALL
Although in Ph+ ALL P-loop mutations and T315I are the 
most frequent,15,36 imatinib-resistant mutations have been 
observed all over the KD. For this reason, the European 
LeukemiaNet recommendations on BCR-ABL1 mutation 
testing in CML underlined the importance of using sequenc-
ing approaches rather than mutation-specific assays, ena-
bling screening for a limited number of mutations only. No 
commercial assay is, as yet, available.51 A series of studies 
have described the setup of home brew protocols, all using 
RNA as a starting material and selectively amplifying the 
KD of translocated ABL1, implemented on various NGS plat-
forms.26-34 Such studies have suggested that BCR-ABL1 KD 
mutation screening by NGS is feasible in expert laboratories, 
and that NGS results are accurate and reproducible down to 
variant frequencies of 1%26-33—although a recent multicenter 
study has highlighted that 3% is a more robust threshold.34 
A schematic representation of a proposed assay design for 
NGS-based BCR-ABL1 KD mutation screening is presented 
in Figure 1.
3.6.1 | Consensus statements
Bone marrow (BM) should be the preferred specimen for 
BCR-ABL1 KD mutation screening in Ph+ ALL. At least 
5  mL of BM should be obtained using ethylenediaminetet-
raacetic acid or sodium citrate as an anticoagulant; heparin 
must be avoided. RNA from mononuclear cells is the recom-
mended template. Selective amplification of the ABL1 KD of 
the fusion BCR-ABL1 allele is recommended. This may be ac-
complished using either of two forward primers, on BCR exon 
1 (specific for the e1a2 fusion, encoding p190BCR-ABL1) or 
on BCR exons 12/13 (specific for the b2a2 and b3a2 fusions, 
encoding p210BCR-ABL1) and a reverse primer on ABL1 exon 
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10. The resulting amplicon may be either used as a template 
for a nested PCR or may be fragmented, provided that the 
final amplicons or fragments are not shorter than 300-400 bp, 
to maximize the likelihood to detect compound mutations. 
Accordingly, sequencing chemistries/cycles producing reads 
shorter than 400 bp are not recommended. For the above rea-
sons, commercial gene panels incorporating ABL1 but using 
genomic DNA as input material and sequencing short frag-
ments are not recommended.
The minimal mRNA region to be screened for mutations 
is that encoding amino acids 235 through 498 of the ABL1 1a 
protein isoform, known to correspond to the KD (reference 
Genbank sequence: NM_005157.5). No mutations should be 
reported outside this region.
The recommended minimum depth of coverage is 1000×. 
Unless commercial kits become available, each individual 
laboratory will be responsible for the optimization of assay 
conditions and for the evaluation of accuracy, precision and 
analytical sensitivity. Given the inherent differences between 
NGS platforms, chemistries, and bioinformatics tools, specific 
recommendations on ranges and thresholds cannot be provided. 
To ensure optimal analytical performance, each laboratory will 
have to define means and criteria for quality control and to en-
gage in regular proficiency testing programs. The Panel sug-
gests that mutations with a variant allele frequency below 3% 
should not be reported. Any variant >3% should be reported 
irrespective of the availability of experimental or clinical 
information regarding its sensitivity profile. Laboratory reports 
should include the following minimal set of information:
• whether the sample is evaluable or not and why (insuffi-
cient RNA quality/quantity; unsuccessful amplification of 
the ABL1 KD of the BCR-ABL1 transcript);
• for each variant detected, listed as nucleotide and amino 
acid substitution, the relative frequency and a clear indi-
cation of whether it has a known or unknown resistance 
profile. The TKI(s) to whom the variant is known to be 
insensitive should be clearly indicated.
The turnaround time for reporting results should be 
2 weeks or shorter.
4 |  DISCUSSION
Many laboratories are currently in the process of introduc-
ing NGS into their routine diagnostic procedures since it has 
proven a robust, reproducible and, in the case of gene pan-
els, cost-effective alternative to SS. Here, Ph+ ALL experts 
analyzed the body of data on the use of NGS for BCR-ABL1 
KD mutation testing in Ph+ ALL and judged whether it was 
sufficiently robust to provide recommendations. So far, there 
has been no randomized clinical trial formally assessing 
the efficacy of a proactive change of therapy based on the 
F I G U R E  1  Schematic representation of assay design for next-generation sequencing-based BCR-ABL1 kinase domain (KD) mutation 
screening. After RNA extraction from bone marrow mononuclear cells and reverse transcription, selective amplification of the ABL1 KD from the 
fusion BCR-ABL1 allele may be accomplished by using two alternative forward primers, either on BCR exon 1 (for the e1a2 fusion; p190) or on 
exon 12/13 (for the b2a2 and b3a2 fusions; p210) and a common reverse primer on ABL1 exon 10. The resulting amplicon may be either used as a 
template for a nested polymerase chain reaction or may be enzymatically fragmented, provided that the resulting amplicons, or fragments, are not 
shorter than 300-400 bp, to maximize the likelihood to detect compound mutations. The kinase domain encompasses amino acids 235-498
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detection of low-level mutations by NGS, and considering 
the low incidence of Ph+ ALL cases and the heterogeneity 
of TKI and chemotherapy combination regimens used by dif-
ferent cooperative study groups, such a trial will hardly be 
feasible. This forced the expert Panel to use the method of 
consensus to shape the statements herein presented.
The Panel assessed the potential value of NGS testing in 
three distinct settings: before and during first-line TKI-based 
treatment; in relapsed/refractory cases; before and after al-
lo-SCT. The first was the most debated setting. The Panel 
discussion highlighted the lack of prospective data and the 
paucity of retrospective data—all obtained with other tech-
nologies (ASO-PCR, D-HPLC, ligation-dependent PCR) 
characterized by variable levels of sensitivity, accuracy, 
and reproducibility. In the great majority of cases, the same 
TKI-resistant mutation detected at low levels at diagnosis co-
incided with that harbored by the dominant clone detected 
at relapse, although some exceptions (patients not relaps-
ing or relapsing with a different mutation) have been re-
ported.12,36,37 Based on observations made in CML, where 
more data are available, a mutant clone present at low levels 
can be expected to undergo Darwinian selection if the TKI 
is not active against the mutation. However, if and how the 
associated chemotherapy may modify the selective pressure 
of TKIs, and whether more or less intensive chemotherapy 
regimens may exert different roles, remains to be assessed in 
Ph+ ALL. Based on the above considerations, the majority of 
the Panel members agreed that NGS at diagnosis is indicated, 
but that NGS results should be restrained from modifying 
the approved conventional therapeutic protocol. NGS should 
rather be used to identify patients at a higher risk of early 
relapse, defined as those carrying at baseline a TKI-resistant 
low-level mutation by NGS. These patients should undergo 
an individualized molecular and mutation monitoring, with 
monthly NGS testing recommended (in the presence of de-
tectable disease) to follow mutation kinetics in order to con-
sider a timely mutation-driven preemptive therapy if MRD 
remains persistently high or tends to increase over time. As a 
matter of fact, it has been reported that resistance-driven mu-
tations expand very rapidly.29 Although no data is currently 
available that demonstrate the benefits of tailoring front-line 
therapy of Ph+ ALL patients based on NGS-detectable mu-
tations at diagnosis, in the era of personalized medicine such 
an approach indisputably represents an attractive opportunity. 
Thus, prospective trials should be designed in the near future 
to properly address this important point.
The Panel, that also included experts in molecular biology 
and NGS testing, additionally engaged in the definition of a 
set of minimal technical and methodological requirements for 
analysis and result reporting. They also underlined that NGS 
should be implemented only in a limited number of highly 
qualified laboratories already involved in MRD monitoring of 
Ph+ ALL patients, so that BCR-ABL1 KD mutation screening 
may be activated in a timely manner on the same RNA or 
cDNA samples used for MRD analysis whenever necessary. 
The centralization of testing will also be required for cost-ef-
fectiveness. Several regional or national networks of expert 
laboratories are already in place, which in turn are involved 
in worldwide cooperative efforts (eg, ESLHO—European 
Scientific foundation for Laboratory HematoOncology). It 
would be advisable for such networks to take the lead in fu-
ture standardization and organization of periodical quality 
control rounds. Harmonization of protocols and coordinated 
definition of standard requirements for sensitivity, accuracy, 
and reproducibility of the results are particularly critical is-
sues. At present, unfortunately, no commercial kit for NGS-
based BCR-ABL1 KD mutation testing yet exists. A common 
NGS kit to be standardized across centers is eagerly awaited, 
since that would increase the number of centers that can per-
form in house analyses.
From a technical point of view, NGS-based BCR-ABL1 
KD mutation screening can be performed on the same RNA 
or cDNA used for MRD testing. Indeed, real-time PCR 
should always be performed first, and MRD results should 
guide the decision of whether to proceed to NGS testing. It 
has been reported that MRD persistence in Ph+ ALL patients 
may hide emerging clinically actionable mutations that NGS 
may timely identify, thus enabling treatment optimization 
aimed to prevent hematologic relapse.29 For this reason, the 
Panel stated that NGS is indicated not only in patients who 
fail to achieve or who lose CHR, but also in those who test 
MRD positive at the end of induction or consolidation ther-
apy. Similarly, the Panel recognized that NGS might provide 
valuable information in patients who display MRD positivity 
after transplant. Knowledge of BCR-ABL1 transcript levels 
is also important to assess the feasibility of NGS testing. In 
CML samples, it has been reported that at values below 0.1% 
library preparation is not always successful, and even when 
it is successful, repeatability is reduced, and false negative 
results are not infrequent.52
In conclusion, we here report the first attempt at defining 
indications for the use of NGS for BCR-ABL1 KD mutation 
screening in Ph+ ALL. Table 1 presents an overview of our 
consensus-based indications. This initiative was fostered by the 
awareness that enhancing the capability of detecting emerging 
mutations and providing the most accurate picture of the muta-
tion status may bring important advantages in defined patient 
settings. At the same time, the Panel of Experts also felt that, 
in order to avoid inappropriate use of non-standardized testing, 
a minimal set of indications had to be defined as to when and 
how to perform NGS testing. A similar effort has recently been 
accomplished for BCR-ABL1 KD mutation testing in CML.53
Although a consensus on a series of position statements 
was reached, the literature review and the Panel discussion 
highlighted the strong need for prospective studies aimed at 
systematically applying NGS for BCR-ABL1 KD mutation 
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monitoring of Ph+ ALL patients in the framework of TKI-
based clinical trials. Such studies, that would greatly benefit 
from the international cooperation of different study groups, 
would help to establish the role of NGS at diagnosis and to 
find the best timing and integration of MRD and mutation 
testing into the clinical decision algorithms.
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